Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Gross Margin: 2013-2017

Historic Gross Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Jun 2017 value amounting to -4,100.00%.

  • Soleno Therapeutics' Gross Margin fell 165000.00% to -4,100.00% in Q2 2017 from the same period last year, while for Jun 2017 it was 0.74%, marking a year-over-year decrease of 1129.00%. This contributed to the annual value of 100.00% for FY2024, which is N/A change from last year.
  • According to the latest figures from Q2 2017, Soleno Therapeutics' Gross Margin is -4,100.00%, which was down 19,501.79% from 21.13% recorded in Q1 2017.
  • Soleno Therapeutics' 5-year Gross Margin high stood at 100.00% for Q3 2013, and its period low was -4,100.00% during Q2 2017.
  • Moreover, its 3-year median value for Gross Margin was 7.52% (2015), whereas its average is -636.51%.
  • Within the past 5 years, the most significant YoY rise in Soleno Therapeutics' Gross Margin was 2,796bps (2016), while the steepest drop was 252,732bps (2016).
  • Over the past 5 years, Soleno Therapeutics' Gross Margin (Quarterly) stood at 100.00% in 2013, then remained steady at 100.00% in 2014, then slumped by 10,630bps to -6.30% in 2015, then surged by 2,796bps to 21.66% in 2016, then tumbled by 165,000bps to -4,100.00% in 2017.
  • Its last three reported values are -4,100.00% in Q2 2017, 21.13% for Q1 2017, and 21.66% during Q4 2016.